Amphastar Pharmaceuticals (AMPH) Competitors

ADMA Biologics (NASDAQ:ADMA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

Do institutionals & insiders hold more shares of ADMA or AMPH?

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 3.7% of ADMA Biologics shares are held by company insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more volatility & risk, ADMA or AMPH?

ADMA Biologics has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.

Does the media prefer ADMA or AMPH?

In the previous week, ADMA Biologics had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 6 mentions for ADMA Biologics and 5 mentions for Amphastar Pharmaceuticals. ADMA Biologics' average media sentiment score of 1.27 beat Amphastar Pharmaceuticals' score of 0.23 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts rate ADMA or AMPH?

ADMA Biologics presently has a consensus target price of $27.67, suggesting a potential upside of 55.34%. Amphastar Pharmaceuticals has a consensus target price of $32.33, suggesting a potential upside of 43.07%. Given ADMA Biologics' stronger consensus rating and higher possible upside, equities analysts plainly believe ADMA Biologics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Amphastar Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Which has higher earnings and valuation, ADMA or AMPH?

ADMA Biologics has higher earnings, but lower revenue than Amphastar Pharmaceuticals. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$426.45M	9.97	$197.67M	$0.85	20.95
Amphastar Pharmaceuticals	$731.97M	1.46	$159.52M	$2.76	8.19

Is ADMA or AMPH more profitable?

ADMA Biologics has a net margin of 45.01% compared to Amphastar Pharmaceuticals' net margin of 19.38%. ADMA Biologics' return on equity of 47.16% beat Amphastar Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	45.01%	47.16%	30.51%
Amphastar Pharmaceuticals	19.38%	22.20%	10.40%

Summary

ADMA Biologics beats Amphastar Pharmaceuticals on 13 of the 17 factors compared between the two stocks.